My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Bristol-Myers Squibb (NY:BMY)

60.77 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Bristol-Myers Squibb

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

20 21 Next >

Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023

August 21, 2023

From Bristol Myers Squibb

Via Business Wire

Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

August 16, 2023

From Bristol Myers Squibb

Via Business Wire

3 Pharmaceutical Stocks to Buy and Hold for the Long Haul

August 11, 2023

Robust pipelines make these three pharmaceutical stocks solid choices for investors looking for stocks to buy and hold for long-term gains

Via MarketBeat

Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts

August 10, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements

August 10, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis

August 08, 2023

From Bristol Myers Squibb

Via Business Wire

Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist

August 01, 2023

Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.

Via MarketBeat

Topics Artificial Intelligence

2 Attractive Large Caps on Sale After Q2 Earnings

July 31, 2023

For investors that like to sift through the underperformers for good values, good factors to identify are market overreaction and healthy long-term outlooks.

Via MarketBeat

Topics Economy

Exscientia is the Sniper of the AI Drug Discovery Industry

July 27, 2023

News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion

Via MarketBeat

Topics Artificial Intelligence

Bristol Myers Squibb Reports Second Quarter Financial Results for 2023

July 27, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma

July 21, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol-Myers Squibb Company (NYSE: BMY) Making Surprising Moves in Thursday Session

July 20, 2023

Via Investor Brand Network

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

July 13, 2023

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

Via MarketBeat

Topics Retirement

Bristol Myers Squibb Launches Supporting You with UC, with Women’s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White

July 12, 2023

From Bristol Myers Squibb

Via Business Wire

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial

July 11, 2023

From Bristol Myers Squibb

Via Business Wire

Arbutus Appoints Two New Executives

July 10, 2023

From Arbutus Biopharma Corporation

Via GlobeNewswire

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%

June 29, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)

June 26, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023

June 17, 2023

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label

June 15, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts

June 08, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023

June 08, 2023

From Bristol Myers Squibb

Via Business Wire

Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

June 04, 2023

From Bristol Myers Squibb

Via Business Wire

Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer

June 05, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Bristol Myers Squibb to Participate in Upcoming Investor Conferences

June 01, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb to Hold R&D Day on September 14

May 31, 2023

From Bristol Myers Squibb

Via Business Wire

Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application

May 30, 2023

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin

Via MarketBeat

Topics Death

Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma

May 30, 2023

From Bristol Myers Squibb

Via Business Wire

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

May 30, 2023

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...

May 26, 2023

From Bristol Myers Squibb

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.